Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL255 Target Snapshot

Adenosine receptor A2b · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
6,716Compounds
730Assays
7Approved Drugs
6,095.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Adenosine receptor A2b shows clinical signal disease relevance led by metastatic prostate cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P29275. Start with metastatic prostate cancer, then reuse UniProt P29275 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with metastatic prostate cancer, then reuse UniProt P29275 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
metastatic prostate cancer

Adenosine receptor A2b shows clinical signal disease relevance led by metastatic prostate cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with metastatic prostate cancer because it currently carries clinical signal support. Linked drugs include ETRUMADENANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adenosine receptor A2b as ChEMBL target CHEMBL255, mapped to UniProt P29275. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Adenosine receptor A2b
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL255
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P29275
Adenosine receptor A2b
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Adenosine receptor A2b is the right protein anchor across sources, using UniProt P29275 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why metastatic prostate cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAdenosine receptor A2b
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP29275
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAdenosine receptor A2b
UniProt AccessionP29275
Component TypeProtein
Sequence Length332 aa

Adenosine receptor A2b

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Adenosine receptor A2b, mapped to UniProt P29275. Sequence length is 332 aa.

Mapped IDP29275
Review nameAdenosine receptor A2b
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Adenosine receptor A2b shows clinical signal disease relevance led by metastatic prostate cancer. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
metastatic prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugETRUMADENANT
Clinical signal Phase II
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugETRUMADENANT
Clinical signal Phase II
pancreatic ductal adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugETRUMADENANT
Clinical signal Phase II
prostate adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugETRUMADENANT
Clinical signal Phase II
prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugETRUMADENANT
Clinical signal Phase II
rectum cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugETRUMADENANT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with metastatic prostate cancer because it currently carries clinical signal support. Linked drugs include ETRUMADENANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemetastatic prostate cancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
3
Phase III
14
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC502,118.0
KI3,419.0
EC50508.0
KD50.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4552275 10.08 Ki 0.0835 Preclinical
CHEMBL5827075 10.0 IC50 0.1 Preclinical
CHEMBL4450864 9.86 Ki 0.137 Preclinical
CHEMBL4464522 9.83 Ki 0.148 Preclinical
CHEMBL4540206 9.81 Ki 0.153 Preclinical
CHEMBL4454481 9.8 Ki 0.159 Preclinical
CHEMBL486478 9.8 Ki 0.157 Preclinical
CHEMBL500634 9.77 Kd 0.17 Preclinical
CHEMBL3121728 9.77 Ki 0.17 Preclinical
CHEMBL483261 9.67 Ki 0.215 Preclinical
Distribution

pChEMBL Value Distribution

288
5.0
337
5.5
480
6.0
664
6.5
739
7.0
824
7.5
374
8.0
178
8.5
77
9.0
13
9.5
pChEMBL
Approved Drugs

Approved Drugs

ADENOSINE
CHEMBL477
Approved 1989
Properties Compare Identifier
Assay Landscape

Assay Landscape

730
Total Assays
2,710
Tested Compounds
3
Assay Types
Binding — 499 assays, 2,710 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 362 1,525 7.1
single protein format 94 690 7.2
cell membrane format 29 209 7.0
assay format 14 286 6.8
Functional — 229 assays, 963 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 190 863 6.6
assay format 29 78 7.0
tissue-based format 5 5 6.0
cell membrane format 3 10 7.2
single protein format 2 7 5.4
ADME — 2 assays, 15 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —
single protein format 1 15 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine